Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Long term conditions: a whole system, person-centred approach)

Innovation 'Elevator Pitch':
Reduce bedblocking and improve ward care by enabling ward access to digital data upon admission of personal knowledge of the patient including This Is Me, My Passport and Risk data, and assist with stepdown process and therapy
Overview of Innovation:
ReMe supports dementia, older people, carers and families and accompanies the person across their care journey. ReMe was trialled and co-produced by dom care, care homes and in wards.
A new breed, we’ve christened ReMe ‘Activity Based’ software, to differentiate from care planning. For patient knowledge and the ability to enhance care comes from activities, not data input. By using algorithms to source bespoke internet images, music and videos and define a profile it’s possible to deliver more person-centred care. At ReMe’s core are activity tools that learn about the person, such as reminiscence and cognitive therapy, and enable discovering calming content for acute care strategies. ReMe stores life stories, preferences and interests and connects with a care circle, as well as creating automated activity reports which can be sent to the user's family.
Around this person-centred care core are business tools each care sector’s needs. Therefore, ReMe achieves an ROI by assisting in client acquisition, care assessment, acute care planning, management and paper reduction, activity creation, scheduling and data collation, whilst providing family and admin reporting. With cross care sector data connectivity and real portability, ReMe becomes part of a dementia acute care strategy.
For care in the community, ReMe’s free with premium subscriber services. With self-management, connectivity, entertainment and activities and by generating data, ReMe supports daily care, celebrates a life, strengthens family links and tackles agitation, depression and isolation, becoming a highly-personalised resource and recourse.
ReMe is used currently in the following care sectors.
For dom care, ReMe improves care, client engagement, reports and generates extra revenue through selling extra hours based on a wellbeing and family connected value added service.
For care homes, ReMe helps families engage in the care process, carers use tablets productively, reduces paper and enhances activities, therapy and reporting. ReMe improves care and saves money.
For hospitals, ReMe is a low-cost means to better know the patient; that improves admission, through digital connection to the care home and dom carer providing access to knowledge of the patients’ ‘day before’ care profile. ReMe enhances person centred care, patient wellbeing, reporting and stepdown.
ReMe is easily adopted with no legacy software or training needs.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
RemindMeCare (ReMe) delivers savings for the NHS through its care in the community self-management functionality reducing admissions, an improved admissions process (i.e. Digital This Is Me, Risk and My Health Passport), enhanced in-ward care, reduced medication and more informed step down.
 
ReMe provides connectivity with care homes, domiciliary care, day care centres and families, and enables better knowledge of the person to be used in person-centred care delivery.
 
Continuity of bespoke, tech advanced activities and therapies, that enhance patient wellbeing, engagement, person centred care and acute dementia care, generate improved patient outcomes, reduced agitation, medication and drugs costs, as well as better informed step down and earlier discharge.
 
Increased availability of personal and risk data reduces risk (and possibly litigation), resort to medication and wellbeing decline, so ReMe aims to reduce bed days.
 
ReMe supports improved family visits and overnight stays through the provision of familiar content and entertainment.
 
Automatic care activities recording, for CQC/admin reporting and research is available.
 
Evidence of value is shown only by the demand and positive feedback received from care homes, LA’s, hospitals and families nationwide but will be formalised shortly.
 
ReMe addresses the Next Steps NHS Five Year Forward View; by reducing A&E/GP visits, making patients information available to clinicians; enabling prescribing apps to help people manage their own health, addressing loneliness and aiding carer respite and assisting LA requirements regarding services provision and monitoring.
 
We’re pioneering this connected care approach in conjunction with SWLCC 5-year strategy, focussing on care quality, safety and cost savings, addressing the defined challenges of avoiding hospital admission, supporting ‘Community services to meet the highest standards and working more closely with primary care, mental health, acute hospital services and social care’. Our participation in the Better Care funded Croydon APA project defines ReMe’s role in the budget shift from hospitals to the integration of health and social care, through the coordination of care. Critically, ReMe addresses recommendations by NICE to focus on person centred and family care support through engaging consumers with a user-friendly product that promotes self-management of illness including long term conditions.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
RemindMeCare delivers support for older people and people with dementia, their carers and families and which is portable and usable by their carers, from home to domiciliary, live-in, day care, residential and ward care. ReMe was developed with people in the NHS and trialled in wards and care homes.
ReMe is a new breed we’ve christened ‘Activity Based’ software to differentiate itself from care planning software. For knowledge of the person and the ability to enhance care is derived from activity provision, not from data input.
By providing self-management tools and engaging activities and by generating data, ReMe supports daily care, celebrates a life, strengthens links with family and tackles agitation, depression and isolation. ReMe becomes a daily highly personalised resource and recourse for those people involved in care.
ReMe’s suite of person-centred care algorithm based activity tools enhance care and are the constant core across all care sectors, and continually learn about the person wherever they may be. ReMe’s the only system that offers bespoke reminiscence and cognitive therapy by sourcing images, music and videos that are unique to the user and so enables discovering calming content for acute care strategies. ReMe stores life stories, preferences and interests with carers and a care circle, as well as creating automated activity reports which can be sent to the user's family.
Wrapped around this person-centred care core are business tools that address the needs of each care sector encountered by the person, including those common to all such as CQC reporting and family engagement.
RemindMeCare goes further, achieving an ROI for care businesses and wards by assisting in care assessment, acute care planning, management and paper reduction, activity creation/scheduling/planning and data collation, whilst providing family, admin and regulatory body reporting. With cross care sector data connectivity and real portability, ReMe becomes part of a dementia acute care strategy for whichever care sector at any time is caring for the person. For the ward, ReMe offers access to the vital knowledge of ‘the day before’ care profile of the admitted patient and the benefits that enhanced person centred care can deliver.
Usable on any platform and with encrypted data, ico compliance (G Cloud pending), ReMe has addressed information governance and digital security.
Please view videos (https://www.remindmecare.com/business/ward/ )
Current and planned activity: 
ReMeApp: self-management care tools that assist maintain care in the community, improve the ability of carers to deliver bespoke care and connect the person with their care circle and with their community; to reduce resort to GP and A&E through enhanced care circle engagement. Dementia care training is included and partnerships with Dementia Pathfinders and Worcester University will be extended achieve delivery.
ReMeData: Integration with Care Planning systems; ie with patient’s systems (such as CMC) and others as required.ReMeGP:  GP Connectivity. Through remote connectivity tools GP’s can remain engaged, be better informed but on a remote basis. The intended result is less resort to disturbing surgery visits. GP connectivity will be release in 2018.
ReMeComm: self-management care tools for those cared for in the community, that match the person cared for with local community activities (A partnership pending with Worcester University, CarersUK, MeetingDem and others. 
What is the intellectual property status of your innovation?:
We are the sole owners of our IP
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Simon Hooper 13/05/2017 - 20:13 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Coronary Artery Disease (CAD) is the leading cause of death world-wide. HeartFlow’s non-invasive technology, FFRct, has been found to accurately diagnose patients with suspected CAD, avoid unnecessary invasive procedures, and reduce healthcare costs
Overview of Innovation:
The diagnosis and care of patients with suspected coronary artery disease is significantly improved by the use of HeartFlow's FFRct analysis. Our process starts with data from a standard Coronary Computed Tomography Angiography (CCTA). High-quality (64 slice or greater) CT scanner images are sent to HeartFlow.

HeartFlow then creates a personalized, 3D model of each patient’s arteries. Where computational fluid dynamics are used to evaluate blood flow and assess the impact of blockages in the arteries. With this actionable information, clinicians can determine the right course of action for each patient.

While FFRct is still in an early  stage of adoption, there are now over 150 publications on the technology. Clinical trials have validated both the diagnostic accuracy and clinical utility. Most recently NICE issued guidance on HeartFlow FFRct, stating "The technology is non-invasive and safe, and has a high level for diagnostic accuracy... may avoid the need for invasive coronary angiography... Based on current evidence using HeartFlow can lead to cost savings of £214 per patient."

CT data is securely (Anonymised CCTA data) and seamlessly sent via our “HeartFlow Connect” once installation is approved by the hospital trust. HeartFlow ensures that the scans and FFRct results and analysis models are acceptable to a sites radiologists / radiographers.
 
Whilst this is an emerging diagnostic its well positioned to become an integral part of standard patient care for those who are at risk of CAD. As this is a new technique HeartFlow provides training to radiologists, radiographers, cardiologists and support staff. We work closely with each site to provide support and training to help evaluate the technology and as they begin to incorporate FFRct into their clinical practice. [A high level overview of HeartFlow’s training support can be found in the Adoption guide published by NICE. (see attached)]
 
HeartFlow FFRct users are invited to educational seminars and we are working on establishing a UK users group to help sharing best practice around FFRct’s use.
 
HeartFlow has received CE mark approval for use in UK/Europe.  CCTA image specifications for HeartFlow FFRct analysis; HeartFlow’s CCTA quality requirements are consistent with those of the Royal College of Radiology (RCR), British Society of Cardiovascular Imaging and the Society of Cardiovascular Computed Tomography (SCCT) performance of CCTA guidance document.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
The use of HeartFlow FFRct can improve patient care, efficiency, and lower medical costs:

Patient Care
  • HeartFlow FFRct provides a physician with both functional and anatomical data, improving diagnostic accuracy, thus reducing invasive procedures and associated complications
  • Improved diagnostic accuracy improves patient care and quality of life
  • Studies suggest that incorporating FFRct lowers patient radiation levels due to decreased angiography
Efficiency
  • Studies indicate that the application of FFRct may result in a reduction of unnecessary angiographies, improved cath lab efficiency, and reduced waiting lists
  • By providing both functional and anatomic data, physicians may be able to reduce the need for and waiting times associated with other diagnostic imaging tests
Cost of Care
  • As demonstrated in the NICE guidance, the use of HeartFlow FFRct can potentially reduce the cost of care. NICE estimates an average savings of £214 per patient. This saving is based on not conducting inappropriate invasive diagnostics.
  • A Japanese study has indicated that the use of the CCTA-FFRct strategy to select patients for Percutaneous Coronary Intervention (PCI) would result in 32 % lower costs and 19 % fewer cardiac events in 1 year compared to the most commonly used CAG-visual strategies. 
 
“The HeartFlow FFRct Analysis provides a definitive understanding of both anatomical and functional findings, without any additional testing or risk for patients. Application of the HeartFlow FFRct Analysis is likely to transform the quality of care we can provide for patients, ensuring the most accurate diagnosis and the best treatment plan, as well reducing the need for invasive coronary angiography – a procedure not without its risks.”
  -  Dr. Joseph Mills, Liverpoool Heart and Chest Hospital
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
As stated in the NICE guidance, the adoption of HeartFlow FFRct in the West Midlands region could improve patient care and outcomes while generating significant savings for the region.
 
We are looking for additional adoption sites and would be interested in hearing from West Midlands Trusts that would like to take the lead in establishing our UK user group.  
Current and planned activity: 
HeartFlow is in early conversations with NHS Trusts and commissioners. A handful of early adopting NHS medical centres have begun to provide HeartFlow FFRct for their patients. HeartFlow is engaging with interested physicians at centres with high quality CT capabilities.

UK Sites where Heartflow FFRct is being used:
  • St. Bartholomew’s Hospital (London)
  • Liverpool Heart and Chest
  • Russell Hall Hospital (Dudley, West Midlands)
  • Freeman Hospital (Newcastle)
HeartFlow is in discussion with other UK site about adoption of FFRct.

Planned / required activity
  • We are looking for additional adoption sites and would be interested in hearing from Trusts that would like to take the lead in establishing our UK user group 
  • Whilst we have undertaken worldwide studies we are always interested in ongoing evaluation / validation and collaborative developments technically and with clinical pathway integration.
  • In the future we plan on conducting clinical trials based & focused on specifically the UK population.
What is the intellectual property status of your innovation?:
HeartFlow has established significant intellectual property and has been issued several patents.
HeartFlow received CE IIA mark approval for use in UK/Europe in July 2011. The technology is also ISO 13485 certified.  

Return on Investment
Savings have been demonstrated in clinical trials (PLATFORM), third party health economic modelling (NICE guidance, Int’l Journal of Cariology 183 (2015) 173-7), and real world experience at early adopting centres.
 
NICE recommendations for Heartflow FFRct (February 2017) state:  “Using HeartFlow FFRct may lead to cost savings of £214 per patient. By adopting this technology the NHS in England may save a minimum of £9.1 million (annually) by 2022 by avoiding invasive investigation and treatment.  
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Regional Scalability:
Liverpool Heart and Chest has performed more HeartFlow analyses than any other site. They have demonstrated clinical and economic benefits to incorporating HeartFlow FFRct into their practice. The uptake is due in part to to the strong support from their regional CCG.
Measures:
HeartFlow is seeking to achieve the following outcomes:
 - Improved patient care: Reduction in unnecessary invasive angiographies and eventually a reduction in waiting times for those patients that need angiographies
 - Reduction in Healthcare Costs: NICE estimates cost savings of 214 GBP per patient. We are working with existing sites to demonstrate real world outcomes.
 - Quality of Life: HeartFlow's clinical utility trial, PLATFORM, demonstrated an improvement in quality of life when FFRct was incorporated into patient care pathways. It is likely that this is in part due to the avoidance of unnecessary interventions. To date we have not seen any adverse events from avoiding invasive procedures.   
Adoption target:
NICE estimates cost savings of 9.1M GBP annually within five years. To reach this objective approximately 35,000 patients would need to have access to a HeartFlow FFRct analysis. 
Read more
Hide details
Ben Forrest 12/05/2017 - 16:12 Detailed Submission 2 comments
6
2
Votes
-99999
Innovation 'Elevator Pitch':
“Up to 35% of patients require heated cannulisation due to fragile or hidden veins”

Airglove is a patient warming system that gently heats the arm, raising fragile or hidden veins, making them easier and less painful to access
Overview of Innovation:
Airglove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intravenous drugs. It gently heats the patients arm up as it forces warm air through a single use double walled polythene glove.


www.greencrossmedico.com/products/airglove

Patient Solution
Airglove warming system works in just 3 minutes gently heating the patients arm to the selected temperature. Its is so easy to use the nurse/practitioner simply selects the chosen temperature setting according to the patients skin type, places the patents arm in the double walled polythene glove and selects start. The patient will feel the warm air fill the glove up and vent away through a single slit perforation and after 3 minutes the machine will automatically stop with an alert sound.

Patient Clinical Considerations
With extended courses of treatment such as chemotherapy repeated cannulation is often required. Airglove can benefit fragile or hidden veins by warming the local area which gently raises the veins allowing for the insertion of the cannula. This reduces the time taken, costs and the number of attempts required which is more comfortable for both the patient and nurse/practitioner.

Patient Comfort
In addition to the benefits of easier cannulisation Airglove can help to make the patient more comfortable and relaxed with its gentle warming system with the confidence that the nurse practitioner will be able to access their veins.

Temperature Settings
The temperature can be selected to suit each skin type sensitive 31.5C, normal 35.5C or slightly heavier 38.5C with the Airglove automatically re-setting itself to normal skin type (setting 2: 35.5C) after each use. After 3 minutes the Airglove unit automatically switches off with an alert sound.
 
Patient Safety
No more improvisation with warm water, heat packs or even heated towels to try and gain access to patients veins which can be a Health & Safety issue.

Approved Medical Device
Airglove has taken 3 years of development, research, testing and clinical trials by Green Cross Medico in conjunction with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust hospital. It was developed as there was a clearly defined and acknowledged need by medical professionals at The Maidstone and Tunbridge Wells NHS Trust hospital oncology department. Further clinical trials will be starting shortly with Cardiff University.
 
Airglove is registered with the MHRA and Certified as a Medical Device.

 
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wealth creation / Clinical trials and evidence / Patient and medicines safety / Person centred care
Benefit to NHS:
Airglove was initially developed for chemotherapy patients who have hidden or fragile veins and especially in patients who are in their 5th or 6th cycle of therapy.

The use of Airglove affords easier cannulation with fewer attempts being required (sometimes up to 6 attempts by 3 different staff can be attempted to access a difficult vein). This improved ease of access not only makes the patient’s experience far less traumatic, but ensures a better clinical outcome and saving valuable nursing/practitioner time and consumables.
 
Data regarding patient experience and resource savings are being collected as part of the patient evaluation trials at Maidstone and Tunbridge Wells Hospital. Evidence from trials undertaken to date appears to support these benefits.
 
Improved hygiene and reduced risk of cross infection will result from the use of Airglove vs currently used methods of locally heating the arm e.g. hot towels or buckets of warm water. Only Airglove’s single use only, double walled polythene sleeve comes into direct contact with the patient’s skin. Heated air is circulated between the double wall of the sleeve and is not directly blown across the skin and so the risk of cross contamination is reduced.
 
Airglove can also be used for other interventions where venous access proves difficult due to fragile or difficult to find veins e.g. routine phlebotomy.
 
“I felt compelled to come up with the original concept which became Airglove in response to cancer patients’ needs when I was General Manager at Maidstone and Tunbridge Wells NHS Trust. My aim was to improve health and safety standards and deliver efficiencies in healthcare worldwide.”
Paula Tinniswood – Healthcare, Transformation & Improvement Consultant
 
“In a 20 bed unit at Maidstone and Tunbridge Wells NHS Trust hospital we have 80 patients per day with 30 to 40 of them require heating before cannulation”.
Keli Tomlin, Macmillian Lead Chemotherapy Nurse – Chemotherapy Unit, The Maidstone and Tunbridge Wells NHS Hospital Trust
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
The West Midlands patients and healthcare system would equally share the benefits described above for the NHS in general.

There are 13 NHS Trusts within the West Midlands having an oncology department.
 
Current and planned activity: 
Current activity:
Airglove has been developed in partnership with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust Hospital (MTW). It has undergone testing by the Electronics and Medical Engineering (EME) trials for temperature control and stability, and on a cohort of healthy volunteers. It is in currently undergoing patient evaluation trials with the Oncology department at MTW.
 
We are also working with Cardiff University to undertake additional clinical trials, along with registering Airglove with the NICE Medical Technologies Evaluation Programme.

Maidstone & Tunbridge Wells NHS Trust are currently using the Airglove.

Planned activity:
The first production of Airglove Unit and gloves will be available by 30/4/17. A few from the first production will be made available on loan free to hospitals who wish to undertake collaborative patient trials.
 
We would welcome patient trials partners from hospitals and clinics within the West Midlands region.
 
What is the intellectual property status of your innovation?:
Airglove is a registered Trademark.


Airglove is protected by International patents some of which have been granted and others are in the application stage via Murgitroyd Patent Attorneys.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regulatory Approvals:
Airglove is registered with the MHRA as a Class 1 Medical Device and is CE marked.
 
The first batch of production Airgloves will be issued with a new medical devices certificate (CE EN60601-01 EN60601-1-2 2007).
Commercial information:
Please see attached for target market/demand forecasts.


Commercially our product will be available from June 2017 as it is in production. Initial research and requirements were highlighted by Paula Tinniswood, Healthcare Transformation & Improvement Consultant who currently runs a Cancer & Clinical Support Division in a large Trust in London
Investment activity:
We would be delighted to receive support from regional trials in the West Midlands, should any of the NHS Trusts like to do a patient evaluation trial within their oncology departments.
Regional Scalability:
We have not implemented in scale in any other region yet, as the product will not be available commercially until June 2017. From this point on it will be available to purchase across the West Midlands region directly from Green Cross Medico until available through NHS supply Chain.
Measures:
The success of the innovation will be measured by the uptake of Airglove throughout all 160+ oncology units throughout the UK. 


This will also be determined by the cost savings to the NHS, along with patient comfort and safety, which will be assessed from the success of the patient evaluation and clinical trials. 
Adoption target:
If Airglove is adopted by the 13 NHS Trusts in the WM region into their respective 14 oncology units, supplying 3 Airglove units per oncology unit, this represents 42 Airglove units using 127,400 gloves per annum. 

This could generate potential savings of £369,460 per annum to the Regional NHS.
Investment sought:
It would be very helpful to have further Health Economics support to capture the 'whole process savings' of using the Airglove system.


Our  trials and experience to date has demonstrated that the use of the Airglove system  improves the efficiency of the nurse/practitioner, coupled to the direct consumable cost savings mentioned previously....in addition to the patient comfort benefits.
Read more
Hide details
Sheena Jack 10/04/2017 - 13:29 Publish 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Radar supports health and social care organisations in holistically managing all aspects of their quality and compliance activity, whether intuitively building a CQC evidence portfolio or managing audit, incidents and risk.
Overview of Innovation:
Radar Healthcare system has been developed using the latest technologies and platforms to ensure a cutting edge and sustainable solution. The system adopts proven business rules in use across the health & social care sector in the UK and incorporates the Care Quality Commission (CQC) guidelines and procedures.
 
Radar Healthcare from Smartgate Solutions has been developed in partnership with knowledgeable and respected healthcare professionals. The system is scalable and configurable to organisational needs to meet both internal and regulatory requirements.

The Radar Healthcare modules help care providers meet their daily operational challenges and associated quality and compliance requirements. 
 
Radar supports organisations by: Taking the worry out of quality & compliance
  • A responsive system, allowing you to visualise and manage risk, training and regulatory compliance across the business domain.
Gain a clear line of sight into performance
  • Intuitive and dynamic dashboards providing real-time visibility of business performance at both location and organisational levels.


Automation of key procedures for operational efficiency
  • Translating business rules and SOP’s into action through our automated workflows and action tracking.
Reduce costs
  • Supporting a systems approach delivering demonstrable ROI across business resources, time and staffing.
 Radar Healthcare is currently in use across multiple service areas including Social Care, Primary Care, Specialist Clinics, Acute Care  and Patient Transport.
 
It’s primary purpose is to assist in ensuring each organisation meets relevant regulatory compliance standards and support organisations reduce duplication and effort in managing that process.
 
It will allow existing processes and procedures to be followed more efficiently and enable the introduction of new processes and procedures that are currently unfeasible with existing systems.
 
Key Facts
  • The system is made up of specific modules, each providing a range of functions that can support organisations in their daily operational activity.
  • All Modules work collaboratively and share data to avoid duplication.
  • Data can be integrated from various sources and other software system.
  • Dashboards and reports can be viewed and created by employees, by department, by directorate or as an entire organisation.
  • Each module has the ability to accommodate pre-configured workflows aligned to your existing SOPs, policies and procedures.
 www.smartgatesolutions.co.uk
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Education, training and future workforce / Wealth creation / Digital health
Benefit to NHS:
Radar Healthcare modules have been developed to help care providers meet their daily operational challenges and associated regulatory requirements. 
 
Adopting proven tool kits and processes, Radar Healthcare ensures compliance with the essential standards relating to the quality and safety of care as defined within the CQC and other regulatory bodies.
 
Cost Improvement (CIP) Opportunities
The CIP opportunities are variable and based upon the modules selected. Efficiency savings are realised through two specific means:
  1. Replacement of existing systems in use across the organisation
  2. Redeployment of posts supporting quality and compliance management and re-deploying skills to vacancies within the organisation
 
A high level simulation exercise exploring how the implementation of Radar could support the reduction of cost within an NHS Hospital in the North of England (approximately 3,500 staff serving a population of c250,000 people) identified potential savings of over £300,000 over a 3 year period.
 
Smartgate Solutions have developed a cost calculator capable of identifying cost against current systems and workforce requirements.
 
Efficiency Savings
Additional efficiency improvements can be realised through:
  • Ensuring compliance with CQUIN targets or other commissioning KPIs
  • Improved efficiency and productivity in managing quality and compliance activity
  • Smartgate can support organisations with their recruitment processes and reduce the time spent undertaking training post employment. Radar allows you to issue training and development content to employees prior to their engagement and for completion online, effectively tracking and monitoring their progress against the training content.
  • Reducing the time spend responding to requests from regulatory bodies and building evidence portfolios. Radar supports the on-going development of evidence portfolios, providing clear audit trails and concise reporting.
  • The system intuitively allows users and organisations to share information, allocate tasks and distribute vital information in real time. It provides a safe and effective way of sharing learning and information.
 Client Testimonial
“We are committed to delivering the highest levels of service and CQC compliance. Radar Healthcare has been the key factor in achieving and exceeding these goals.“
John Butterfield, CEO, ER Systems
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Radar supports providers and commissioners of health and care services to effectively manage and monitor their quality and compliance expectations, deliverables and regulatory requirements with greater efficiency and often with greater effectiveness.
 
Radar enables organisations to re-deploy their scarce resources to focus on the delivery of care, freeing clinical expertise from administrative activities. 
Current and planned activity: 
Current NHS Activity:
Radar is currently utilised by numerous providers of health and care services, many of which provide NHS services.
 
We are currently engaged in discussions with both CCGs and NHS Foundation Trusts.
 
At present we are exploring opportunities to grow our engagement with NHS organisations and are seeking support and guidance from colleagues at WMAHSN, Medilink WM and the wider regional health and social care communities.

Planned/required activity:
  • Procurement / Adoption of: -  Growth and increased adoption of Radar across NHS provider and commissioner organisations  
  • Partnership: We are interested in exploring partnership opportunities with NHS organisations that may help to realise a financial ROI
What is the intellectual property status of your innovation?:
All product IP is wholly owned by Smartgate Solutions Ltd
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Tom Lindley 30/03/2017 - 09:44 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Stratification of patients into Risk Groups greatly enhances management of long-term conditions, COPD, Diabetes, Heart Failure, etc also supporting early discharge preventing readmissions.
Overview of Innovation:
Stratification of patients into Risk Groups, even for the same condition, greatly enhances the focus, scalability and agility in response to changing demand. Used to manage people with long term conditions such as COPD, Diabetes, Heart Failure, etc…… as well as supporting early discharge to prevent readmissions.
  1. Population-level Low-Risk Patients (75%): Free for BYO devices (smart or text message) for self-management and education. No remote monitoring but data can be shared with GP systems for access by all clinical stakeholders. Minimum cost to the NHS. Scalability is limitless. Activ8rlives4 Wellness and Food Diary App is available FOC via the App store and Google Play.
  2. Rising Risk Patients (20%): Where there is no smart phone availability or poor IT skills: CliniTouch Vie as below. Where Patients own Smartphone/Tablet and have WiFi: Activ8rlives Lung Health, Diabetes Health and others. Medical monitors could be prescribed on loan initially on early discharge (as one use case) and then transitioned to BYO Smartphones and monitors. Alternatively, they may be stepped-up by prescribing further monitors and data reviewed remotely at greater frequency.
High Risk Patients (5%): CliniTouch Vie: locked-down tablet provided with integrated 3G for connectivity, intensive monitoring, education and empowerment with integrated direct messaging and video support. Dynamic care plans and intelligent algorithms enable automatic triage for healthcare team. Fast, simple and quick to implement for the most at-risk and vulnerable of patients.

For further information contact
Kevin A. Auton, PhD, Managing Director, Aseptika Limited kevin.auton@aseptika.com www.activ8rlvies.com
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Spirit Healthcare: Leicester City CCG, combining telemonitoring, specialist nurse interventions and health coaching in COPD, demonstrated reduced admissions by 67% and also improved patient’s experience of care. http://www.magonlinelibrary.com/doi/10.12968/bjhc.2016.22.3.123
  1. 67% reduction in unscheduled admissions amongst patient cohort - multiple regression analysis revealed that CliniTouch telemonitoring (Spirit Healthcare) was the only intervention that statistically significantly (P<0.05) reduced unscheduled admissions.
  2. Overall reduction of 9.1% in all COPD admissions - despite the harsh winter of 2013/14, there was an overall reduction in all COPD admissions, easing winter pressure and bed blocking.
  3. Effective in managing re-admissions – number of admissions per head reduced from 3.13 to 1.02 per year (p<0.001). Nurse interventions required to manage patients also reduced, improving caseload management. The benefits were realised across the whole health economy. 
  4. Improved patients’ experience of care – patient feedback demonstrated higher levels of confidence, knowledge about their condition and positive behavioural change. 
Activ8rlives Lung Health (Sensor 3) telehealth reduced unplanned admissions and improves self-management. Undertaken clinical trials supporting Self-Care in Cystic Fibrosis (Papworth Hospital), COPD and Bronchiectasis (Portsmouth NHS) and on-going in Liverpool Heart and Chest Hospital for 45 COPD patients (Dr Dennis Wat and Mark Jackson, funded by NWC AHSN). Aseptika is an innovation partner for the Sheffield NHS Test Bed.
Liverpool Heart & Chest Hospital, Knowsley Respiratory Community Team. Sensor 3 self-care project allows patients with COPD to monitor and track their vital signs at home, using a secure and easy to use Lung Health 3 App, developed by Aseptika Ltd. The whole process takes approximately 12 minutes each day. The patients are provided with the equipment to allow daily measurements of blood pressure, heart rate, oxygen saturation, body weight, temperature, peak flow, FEV1 and physical activity levels. The measured data is displayed as simple charts. 
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Patients are educated and supported to interpret the data to enable improved understanding of their health status.
  1. Prevent unnecessary admissions as patients have access to 24/7 the COPD rapid response team as soon as there is any health deterioration for treatment to prevent unnecessary admission into hospital. The collected data is currently being analysed by Knowsley Respiratory Community Team.
  2. Technology improves patient’s confidence in managing their COPD. For patients who experience frequent infections and disease exacerbation, this can be a lifeline. In Liverpool 90% of participants would recommend to Friends and Family. 60% would be prepared to make a financial contribution of £300 to support costs.
Current and planned activity: 
Spirit Healthcare group of companies can now provide one of the most comprehensive range of solutions to support patients of all ages, all IT abilities, all levels of disease severity and across a wide range of disease areas: respiratory, cardiovascular, diabetes and frail elderly.

Aseptika currently have in development: (a) on-ward and home-use sputum test for Pseudomonas aeruginosa (patent protected); (b) BuddyWOTCH – a 3G connected wearable medical device (SpO2, HR, Temperature, Respiration Rate with Sit-to-Stand and 5-minute walk test) – patent applied for; (c) a population screening test for Atrial Fibrillation using pulse oximeter technology (patent protected), and (d) Bluetooth inhaler usage monitor.  
What is the intellectual property status of your innovation?:
IP is retained by respective companies within the Spirit Healthcare group of companies.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
3
Read more
Hide details
Kevin A. Auton 12/01/2017 - 10:55 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Optimised Equivalent® to best performing & highest volume branded orthopaedic implants (>1,000,000 patients), coupled with significant savings. Equivalent manufacture, materials, tolerances & sizes, along with operational technique & instrumentation.
Overview of Innovation:
The UK is the first country in the world to benefit from applying the principle of generics to orthopaedic products. Generic medicines have been a core part of the NHS since the 1980s, offering the same clinical outcomes for patients as originator drugs and now contributing over £12 billion in savings every year that can be reinvested into the health service (1)

With >66,000 NHS hip replacement operations performed every year (2) switching to generic hip implants from the current market leaders, the NHS could save up to £120 million by 2020 - enough to fund over 1,400 junior nurses every year (2,3,4)

This is well-timed following Lord Carter’s Review, which found that large efficiency savings can be made by all NHS hospitals – notably in orthopaedics. Some of these savings can be made by reducing the current variation in patient outcomes (5)
 
Evidence from over 1,000,000 hip replacement operations in published registry data shows that some of the most widely used devices with the lowest possible revision rates can be provided at a significantly reduced cost due to patent expiration. Orthimo have produced Optimised Equivalent® implants to the branded versions, providing significant cost savings without compromising patient outcomes.

The manufacturing of the Optimised Equivalent® implants are by well established suppliers with many decades of experience in manufacturing orthopaedic implants for the large Orthopaedic companies, further strengthening the equivalence value proposition.  Both the surgical instruments and techniques are also equivalent.

As a further indicator of reassurance, the Department of Health recently purchased a significant quantity of Optimised Equivalent® implants through a forward buying fund, which can be obtained via NHS Supply Chain.
 
At a time of unprecedented cost pressures on Healthcare systems worldwide, Optimised Equivalent® implants make a valuable contribution towards maintaining high quality hip replacement services within the limited resources available.

This means patients receive the best clinical outcomes at significant cost savings for hospitals.

http://www.odep.org.uk/Product.aspx?pid=2301

http://www.beyondcompliance.org.uk/product.aspx?pid=2301

https://my.supplychain.nhs.uk/Catalogue/product/fjh10279

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence
Benefit to NHS:
Orthimo provide equivalents of the best performing and most commonly used branded orthopaedic implants, as proven by registry data of over 1,000,000 patients. Similarly to generic pharmaceuticals, which the NHS already takes advantage of, Orthimo products come with significant savings of 30-60%. This could save the NHS up to £120million by 2020.
 
These can be provided with minimal disruption to services and procedures due to the sizes, instrumentation and operative technique being equivalent to the most commonly used branded products. They are available through a simple and transparent pricing structure, which can be via the Total Orthopaedic Solutions, Chester or NHS Supply Chain frameworks.
 
As an indicator of reassurance, the Department of Health recently purchased a significant quantity of Optimised Equivalent ® implants through a forward buying fund, which can be obtained via NHS Supply Chain. With most Trusts using one or more of the branded reference components, a transition to make savings has never been easier.
Initial Review Rating
2.60 (1 ratings)
Benefit to WM population:
Orthimo provides generic versions of the best performing hip implants, this means patients in the West Midland area can receive the best clinical outcomes at significant savings to the hospital and trusts in the region. 
 
In the West Midland approximately 6,000 hip replacements are performed per annum. If, at a conservative estimation, these cost £700 each on average, generic hip implants could save the West Midland area over £1.5m per annum.
Current and planned activity: 
With Optimised Equivalents being available via all Orthopaedic frameworks, Orthimo are seeking Surgeons to conduct small volume evaluations or for Trusts to allocate a proportion of their hip work.

As with the generic pharmaceutical industry, there is a need to establish a policy change to ensure the responsible and active use of generic orthopaedic implants.
  • Procurement: -  Require sales and marketing to Trauma & Orthopaedics departments and procurement
  • Evaluation - Seek ‘Beyond Compliance’ service evaluation centres for uncemented range
  • Adoption:- Seek Hospitals/Surgeons to conduct small volumes of procedures
  • New Product Development:- Require experts to propose and support development of new products
What is the intellectual property status of your innovation?:
All IP resides with Orthimo.

Orthimo holds BSI CE Mark for all implants.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
Optimised Equivalents use the most common and best performing branded reference products. These are used in most Trusts across the country, and so an introduction will have minimal disruption. We use the same sub-contracted manufacturers and logistics which the large companies use, and so supply can be scaled rapidly. 
Measures:
Our products are being used via the Beyond Compliance process. This data will be used to apply for successive ODEP ratings when the criteria are acheived. 
Adoption target:
We are looking for Trusts to use Optimised Equivalents for their low risk, common primary elective total hip replacement procedures. It has been estimated that this would be in excess of 60% of cases. 
Read more
Hide details
Oliver Wylie 09/01/2017 - 15:16 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':

Converting Clinical lab based Xanthochromia procedure into Near Patient testing/Point of Care Procedure using pocket sized spectrometer.

Overview of Innovation:

I am thinking of converting Xanthochromia lab based spectrophotometry procedure (SAH/fatal accidents/Head injuries) into Point-of-care/Near patient testing (POCT) procedure. A small pocket sized spectrometer is going to come soon in the market.

The device is a molecular sensor with cloud based database. The company offers developmental tools to build the database, by scanning  every material that exists in this world..from paracetamol to material science. 

Converting this to POCT offer some advantages: The patient's sample need not travel long from A/E to Lab. AE consultants/Nurses themselves without much technical comptency can perform the procedure with ease and early intervention/timely diagnosis is made possible: facilitating quicker clinical decisions, reduce length of stay..improve morbidity and mortality. The Challenge ahead is converting this device into a FIT FOR PURPOSE medical diagnostic POCT device.

Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health / Patient and medicines safety / Person centred care
Benefit to NHS:

Converting this to POCT offer some advantage: The patient's sample need not travel long from A/E to Lab. AE consultants/Nurses can perform the procedure with ease and early intervention/timely diagnosis is made possible: facilitating quicker clinical decisions, reduce length of stay..improve morbidity and mortality. The Challenge ahead is converting this device into a FIT FOR PURPOSE medical diagnostic POCT device.

Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:

Converting this to POCT offer some advantage: The patient's sample need not travel long from A/E to Lab. AE consultants/Nurses can perform the procedure with ease and early intervention/timely diagnosis is made possible: facilitating quicker clinical decisions, reduce length of stay..improve morbidity and mortality. The Challenge ahead is converting this device into a FIT FOR PURPOSE medical diagnostic POCT device.

Current and planned activity: 

Contacted the chief technology officer of the Company (Consumer physics) awaiting response for modifying the device into POCT medical diagnostic device. If green signal given may discuss with NHS trust and start the joint development/clinical trial/evaluation/validation/verification using NHS trust as base 

What is the intellectual property status of your innovation?:

N/A

Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
GANAESH 27/10/2016 - 01:21 Publish 1 comment
4
1
Votes
-99999
Innovation 'Elevator Pitch':

The Recipe for Workforce Planning is an easy-to-use online tool driven by a dynamic process map.The Recipe is a repository for best practice and facilitates peer support through a discussion forum.

Overview of Innovation:

The Recipe for Workforce Planning is an easy-to-use online tool driven by a dynamic process map; users click on each stage of the process to access resources and view the activities needed to complete that stage. The Recipe is a repository for best practice and facilitates peer support through a discussion forum.

This unique resource is the first of its kind, developed by Health Education England working across the West Midlands, and is being shared for use across Health Education England.

The Recipe process map, created in collaboration with workforce planners across the West Midlands, shows the stages that should be completed in order to create a good workforce plan:
 
Users can click on a stage to open a Stage Page showing:

  • Ingredients - documents and resources needed to complete that stage which users can download.
  • Method - activities necessary to complete that stage with assigned roles.
  • Hints and Tips – any useful advice or intelligence that will support the completion of the stage

The Recipe also includes:
 
What should I be cooking this month?
Each stage in the Recipe has a date range during which that activity should be completed.  Users will be able to see the stages within the Recipe which are currently ‘active’ at the time they visit the site.
 
Roles and Responsibilities
Each of the activities within a stage has an assigned role e.g. Workforce Planner, Finance Lead.  Users will be able to sort and filter the site to view only the stages and activities relevant to their role.
 
Discussion forum
The Recipe has a discussion area where planners can share ideas and ask questions or queries.  
 
Cookbooks
Users can select their favourite resources from the site (Word, Excel, PDF documents) and download these into a pack, or Cookbook.  There are also readymade Cookbooks for particular users and scenarios e.g. Workforce Planning for Beginners, Meeting with the Executive Team, Workforce Planning for Commissioners.
 
Links and Resources
The resources – or Ingredients – available to users for each stage are added to and updated as new resources become available.  However, there may be useful resources, reports, articles or links that are not relevant to a particular stage but may be of interest to workforce planners.  These are available on the Links and Resources page that will include an archive of all the resources on the site.
 
The Recipe also includes a search function and an interactive glossary. 

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Education, training and future workforce / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:

Provides an easy-to-use online tool driven by a dynamic process map, demonstrating what good workforce planning looks like. This unique resource is the first of its kind and can be used in any clinical or non clinical setting when looking to effectively workforce plan.

Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:

Provides an easy-to-use online tool driven by a dynamic process map, demonstrating what good workforce planning looks like. This unique resource is the first of its kind and can be used in any clinical or non clinical setting when looking to effectively workforce plan. This resource was developed by the West Midlands and includes templates and resources which are currently being used across the region.

Current and planned activity: 

We have launched this resource nationally and are actively promoting this resource across the West Midlands, incorporating any feedback we receive.

For more information or to access the Recipe for Workforce Planning click here

What is the intellectual property status of your innovation?:

Health Education England.

Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Sarah Chamberlain 25/10/2016 - 09:44 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Tipsim® is a completely new product producing long lasting improvements in sensorimotor abilities of the hand in rehabilitation after brain damage, such as stroke, craniocerebral trauma or other neuro diseases e.g. Complex Regional Pain Syndrome.
Overview of Innovation:
Tip-stimulation with Tipstim® facilitates long-lasting therapy procedures. By sensory stimulation of the finger tips, Tipstim® drives plasticity processes in cerebral areas involved in the activation of the hand and fingers. Specially designed stimulation patterns – developed over many years of research & trials at the Institute for Neuroinformatics at the Ruhr University Bochum – are generated by a small, portable electronic pulse generator and applied directly to the finger tips via a completely new and highly-sophisticated therapy glove. The Tipstim glove® is the first product of its kind to utilise a new advanced medically approved conductive and biocompatible textile.
 
The therapy is completely painless, without side-effects and very easy to apply. The patient simply pulls over the glove, connects it to the pulse generator and starts the therapy session once a day for 1 hour. The therapy does not demand any special attention from the patient. Due to the small size of the pulse generator, the therapy can easily be integrated into everyday life and home. In principle, therapy can be applied everywhere, even when out walking.


 The proven efficiency of Tipstim® results from stimulation pattern specially designed for most effective enforcement of neuroplasticity processes. Clinical studies show that these special patterns produce cerebral changes which lead to persistent improvement of a patient’s sensorimotor abilities. This especially true with sensory and proprioceptive deficits which have shown a greater recovery than with standard rehabilitation therapy alone
 
Studies have shown that sensory stimulation drives plastic processes in the brain areas activated by the stimulation. This induces reorganisation in and around those brain areas that became dysfunctional by stroke or other brain injuries. This reorganization facilitates reactivation of cortical tissue that has preserved some functionality. The resulting remodelling of cortical circuits then mediates functional recovery.
 
Tipstim® is a clinically tested and CE approved product. The efficacy & safety of Tipstim® therapy has been proven in rigorous clinical trials.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Person centred care
Benefit to NHS:
Stroke is the UK’s third biggest killer.
 
First-time incidence of stroke occurs almost 17 million times a year worldwide; one every two seconds. Stroke is one of the largest causes of disability – half of all stroke survivors have a disability.
 
In the UK there are 152,000 recorded incidences of stroke a year and currently over 1.2 million stroke survivors. The economic costs of stroke in the UK from a societal perspective totals around £9 billion a year (Source: State of the Nation Stroke statistics - January 2016). The average cost of care (acute & rehabilitation) per stroke patient is currently £23,315 (National Audit Office. Progress in improving stroke care..., (February 2010). NAO Report (HC 291 2009-2010))
 
Over a third of stroke survivors in the UK are dependent on others.
 
Tipstim® is a completely new product to improve sensorimotor abilities of the hand in rehabilitation after brain damage, such as stroke, craniocerebral trauma and other neurological diseases such as Complex Regional Pain Syndrome.
 
Tipstim® comprises a small, battery powered electronic pulse generator unit and a close fitting glove that delivers the neurostimulation at the finger tips. Due to the compact size of the pulse generator, the therapy can easily be integrated into everyday life. In principle, therapy can be delivered everywhere, even during walking or when reading or watching television.
 
Clinical trials have demonstrated that the stimulation provided by Tipstim®  demonstrates a persistant reactivation of affected brain areas responsible to sensory and motor control of the hand and fingers. Moreover, balancing processes in adjacent non-affected brain areas are promoted.
The result is a substantially improved sense of touch as well as an improved mobility of the concerned hand.
 
The sensory & functional improvements resulting from Tipstim® neurostimulation have been demonstrated to last longer than for traditional therapy alone.
 
The Tipstim® is self contained and can easily be used by the patient in their own home. This reduces the frequency of hospital / clinic visits, frees up therapist time and would enable more patients to be treated than is currently possible.
 
Furthermore, the sensory and functional improvements resulting from the Tipstim® therapy will increase the patient’s ability to carry out task of daily living and will therefore increase their independence, thus reducing the need for additional care and support – with resultant manpower and monetary savings.
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
The West Midlands has the highest mortality for stroke in England in people over 65.
 
The region’s ethnic diversity and socioeconomic status also reflects in a higher than average incidence of strokes as people of black and South Asian origin are at double the risk of stroke as are those living in the most economically deprived areas of the UK (West Midlands has 28.1% of its population in the most deprived national quintile)
 
These statistics demonstrate that the demand for stroke rehabilitation services will be higher than the national average and therefore the opportunity to make a significant impact will be greater for therapies such as Tipstim®.
 
The region also has the lowest percentage of patients returning to their usual place of residence, and this is statistically significantly lower than the England average. Improved  independence and post stroke rehabilitation would help to address this and enable people to return to their own homes and live independently.
Current and planned activity: 
We are currently undertaking a pilot multicentre clinical trial of Tipstim® at the Countess of Chester NHS Foundation Trust, Chester.
We would welcome the opportunity to engage with the West Midland’s Stroke rehabilitation communities to raise awareness of our Tipstim®.
In addition, we wish to explore support for business model development and delivery strategies for NHS adoption and or private procurement.

We are also very interested in conducting a cost benefits analysis health economics study of therapeutic intervention with Tipstim®.
What is the intellectual property status of your innovation?:
Tipstim® is protected via granted patents and registered design rights held by the parent company.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Read more
Hide details
Bharat Vadukul 21/09/2016 - 12:15 Detailed Submission 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
The i-THRIVE programme aims to improve children and young people’s mental health outcomes by working with 30 sites across the country to implement the THRIVE framework.
Overview of Innovation:
i-THRIVE is national programme of innovation and improvement in child and adolescent mental health. It is an NHS Innovation Accelerator and is currently being implemented in national accelerator sites across the country. It is delivered by supporting localities to implement the THRIVE Framework through their CAMHS transformation and service improvement programmes.

i-THRIVE Community of Practice 
More than 30 sites make up the i-THRIVE Community of Practice. The Community of Practice includes organisations that are using the THRIVE framework as the basis of their CAMHS transformation and improvement programmes who then share learning about the implementation of THRIVE and how it can be adopted to fit with their local plans for service redesign. Nearly 25% of the young people in England live within a locality that is a member of the i-THRIVE Community of Practice.

THRIVE
THRIVE Elaborated (Wolpert et al, 2015) can be downloaded here: THRIVE Elaborated

i-THRIVE
i-THRIVE is the implementation of the THRIVE conceptual framework, translating the THRIVE core principles into models of care that fit local contexts. Key to this process is the use of evidence based approaches to implementation.
 
i-THRIVE supports the provision of services using a whole-system, or place-based, approach to the delivery of child mental health services. This involves taking a population approach to delivery of care; enabling integration across health, care, education and third sectors, and a central focus on delivering improved outcomes for children and young people.
 
Choice and personalisation of care are core values and these are delivered in part through systematic implementation of shared decision making. To support this, a range of validated measures, tools and educational programmes have been developed by partners and are included in the i-THRIVE Implementation Toolkit, including the CollaboRATE measure, Option Grids and shared decision making training through the i-THRIVE Academy.

i-THRIVE Partnership Organisations
i-THRIVE is delivered through a partnership between the Anna Freud National Centre for Children and Families, the Tavistock and Portman NHS Foundation Trust, the Dartmouth Centre for Healthcare Delivery Science and UCLPartners.

Further Information
Further information about i-THRIVE and examples of successful implementation in sites can be found at http://www.implementingthrive.org/. For the latest news and updates you can also follow us on Twitter: @iTHRIVEinfo.
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Innovation and adoption / Person centred care
Benefit to NHS:
i-THRIVE and the THRIVE framework have been developed to align with and to support established system transformation and quality improvement methodology. The i-THRIVE model is aligned to emerging tariff payments and is identified within Future in Mind as a suggested model of care.
 
i-THRIVE encapsulates many of the key strategic requirements for delivering CAMHS over the next few years. The NHS Five Year Forward View emphasises services being person-centered, the importance of early intervention, taking a whole system approach and enabling self-care, all of which are core to the THRIVE framework and in the delivery of i-THRIVE. By supporting sites to deliver i-THRIVE we will be helping them to deliver the changes called for in Future in Mind.

Expected benefits include increased proportion of young people accessing CAMHS with higher proportional improvement in vulnerable groups due to outreach and the location and accessibility of assessment services. There will be increased use of community services, self-care and peer-support networks as a result of effective signposting. We expect to see a reduction in waiting times and increased engagement with services with young people involved in co-designing services, their care and in peer-support networks. Efficiency gains are also expected.
Initial Review Rating
4.40 (2 ratings)
Benefit to WM population:
We are currently working with sites in the West Midlands to support them in the delivery of i-THRIVE.
Current and planned activity: 
i-THRIVE is currently supporting 30 sites across the country to develop and implement the THRIVE framework as part of their CAMHS transformation plans. The programme is funded by Health Education England, The Health Foundation and the NHS Innovation Accelerator to directly support NHS sites  and their partners in local government, education and the third sector, by providing learning and development resources, sharing evidence based tools for implementation, the sharing of good practice and support for evaluation.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
3
Read more
Hide details
Emma Louisy 06/09/2016 - 14:24 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Flo-Tone CR is a tool helping patients acquire good Maintenance & Technique in using Pressurised Inhalers, teaching how to Inhale SLOWLY and STEADILY. Inhaler Technique Skills are important and a major theme in BTS, GINA and NICE guidance.
Overview of Innovation:
Flo-Tone MDI (also known as Flo-Tone CR) uses a ‘Positive’ Coaching Whistle to help patients learn to inhale SLOWLY and STEADILY. Whistle Signal is a prompt for the canister to be pressed releasing the medication & the duration of the Whistle helps the professional to coach the patient towards correct use.
Pressurised inhaler mouthpieces come in a variety of shapes, accordingly Flo-Tone was originally produced in ‘Circular’ & ‘Regular’ Models. A new improved Flo-Tone CR now fits all mouthpiece shapes by fitting inside the pMDI mouthpiece. The new design ensures all pMDIs produce a whistle at the same flow rate, helping standardise technique.
Studies have been conducted with the new Flo-Tone to ensure that it delivers the full dose. The first study detailing the development of the improvement & its performance was presented at BTS 2015 & subsequently at DDL26.
Available on prescription, the improved Flo-Tone CR can be used with a pMDI simulator (Trainhaler) for training & with the Patient pMDI. It incorporates a cap so that it can be left in situ on the Inhaler. It also includes a rim on the mouthpiece to help patients get their teeth out of the way of the aerosol spray.
We have tested Flo-Tone CR with a variety of inhaled medications (Flutiform, Clenil, Ventolin, QVAR and Sirdupla) – in each case the respirable dose (ie that part that reaches the lungs) delivered for the medication plus Flo-Tone closely matched that of the device alone & in each case unwanted throat deposition was reduced.
•Flo-Tone CR controls the resistance of the pMDI, thereby standardising the flow rate at which  
  Flo-Tone CR whistles
•Provide inhalation & coordination guidance
•Sounds (20-25 L/min)
•Drug delivery improvement = Therapeutic Improvement
•Less throat deposition – potentially less unwanted Throat Side-Effects
•Better control - less breakthrough – less SABA needed
•Better control – less hospitalisation 


• Spacer & Mask with anti-Microbial & anti-static properties
Collapsible – helps with storage & travel
• Visible valve movement - see that the drug is being Inhaled
• Suitable for adults & children
• Performance validated with pMDI’s
• Accepts all pMDI’s available
• Available with small & medium mask


• Ideal for emergency services use, schools & within General Practice & Hospitals for reversibility testing
• Single patient use
• Economical & environmentally friendly
• Performance validated with pMDI’s
• Available in bulk pack 
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
There have been many papers published, detailing the misuse of pMDI among patients;
Clement Clarke International have used their expertise to concentrate on this area of products. This
has led to the introduction of the ‘Inhaler Technique Training’ range. Each device is targeted at the
training of inhalation technique, guiding patients to inhale at the correct flow rate for pMDI use.
 
Inhaler technique errors occur in the hands of patients and healthcare professionals. It has been
demonstrated that the majority of healthcare professionals cannot demonstrate correct inhaler use
to their patients. It is not therefore surprising that patients are mostly unable to demonstrate good
inhaler technique. The consequences are significant; patients take higher doses to compensate for
lack of efficacy from medication lost through poor technique, this results in poorer control,
hospitalisation and increased healthcare costs.

The Clement Clarke ‘Inhaler Technique Training’ range delivers more reliable, more effective and patient friendly usage of medication and treatment (therapy) delivery.
Benefits summary
  • Patient friendly medication management and use
  • More effective and accurate delivery of medication to lungs
  • Reduced number of hospital admissions
  • Reduced number of un-planned clinical interventions
  • Reduced associated therapeutic costs
  • Improved patients’ health and quality of life
  • Available on the National Drug Tariff
  • Low cost devices
  • Available for immediate use
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
The West Midlands region provides a great opportunity for rapid realisation of the benefits of improved inhaler training from a clinical, economic and patients’ quality of life perspectives.

All the required products and training materials are currently available for instant deployment and would offer significant benefits to those GP practices or secondary care providers willing to challenge existing ineffective training and delivery mechanisms and who would act as either the Regional or National adoption lead.
 
A comprehensive breakdown of the tools and devices required for a GP practice has been provided in an attached document (Essential Requirements for GP Practice Inhaler Training Kits).
Current and planned activity: 
Current NHS activity
Key areas of Contact are Lung Function & Respiratory Medicine which include Respiratory Physiologists & Respiratory Nurses both in Adults & Paediatrics.
 
Flo-Tone has been adopted by Wolverhampton CCG.

Planned/required activity
As a Manufacturer, Clement Clarke undertakes an extensive R&D program and also undertakes On-Site Clinical Trials with GP Practice & Secondary Care.
However, research and trials support partners would be welcomed to further develop the evidence base demonstrating the benefits of improved staff training with associated patient benefits.
In addition, Health Economic studies would also be welcomed to quantify the medication and admission cost savings that would be achieved. This would supplement the Isle of Wight study and include a wider geographical and ethnic / demographic patient cohort.
What is the intellectual property status of your innovation?:
All intellectual Property for devices and training is held by Clement Clarke International
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
3
Read more
Hide details
Anthony Silvio Philips 31/08/2016 - 10:46 Publish Login or Register to post comments
4
1
Votes
-99999
Innovation 'Elevator Pitch':
An engaging educational board game and HTML5 web app to help children with Cystic Fibrosis, and their families, to improve their understanding of the condition and how to manage it.
Overview of Innovation:
The game is designed to help children and families manage Cystic Fibrosis more effectively. Originally created by specialists at Coventry & Warwickshire Partnership NHS Trust to help healthcare professionals develop a more effective relationship with young patients and their families. The game was so effective that Focus Games Ltd was asked to redesign and streamline the game and make it available to a wider audience.

The game is designed for between 2 and 4 individual players (or small teams of players) who compete to move around the board answering CF-related questions and scenarios correctly. The game is very easy to play and doesn’t require a specialist facilitator; anyone can play the game. This makes it ideal for use in the home and at school with family, friends and schoolmates.
 
Objectives
To help young patients, their families and friends to improve their understanding of Cystic Fibrosis and to manage the condition more effectively.
 
A patient engagement tool for healthcare specialists to use:
  • Children with Cystic Fibrosis
  • Families & friends of CF patients
  • Schools
  • Public health awareness
Can be used in:
  • CF clinics
  • Other healthcare settings
  • At home
  • In school
The board game is very portable, the rules are very simple and specialist facilitation skills are not required so the game can be played by anybody in any setting.
 
The board game is competitive and accommodates up to 4 individual  players, or teams of players. Games last between 45 and 60 minutes.

The HTML5 web app is a simplified version of the board game designed for individuals to use on smartphones, tablets and desktop PCs. However, it can also be used with groups on tablets, screens and interactive whitebboards etc.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
The original game was developed by Coventry and Warwickshire Partnership NHS Trust and Focus Games Ltd has refined and reworked the game to make it more engaging and more likley to suceed as a commercial product. This process was supported byMidTECH Innovations (NHS Innovations West Midlands).

Benefits to the NHS include:  
  • Increased  knowledge of CF not just for the patient but for the whole family and improved engagement with the CF Team - This would help give children and young people a sense of control in managing their condition. Symptoms are recognised by CF patients and parents early and acted upon so infections are treated quickly therefore less time would be spent as in an inpatient making savings on bed space and staffing.
  • Increased understanding of treatments - Children can express and explore their fears and emotions in a safe place. Play provides the medium to help manage these feelings and therefore promotes resilience
  • Improved  compliance with treatment – Children and young people with CF will often have multiple treatment regimens to follow. The CF game gives an understanding of why particular treatments/medicines need to be adhered to. Compliance would mean improved and less stressful visits for treatments and hospital appointments where children are having to be persuaded  to comply with cough swabs/lung function tests etc. This can take up a considerable amount of time for nurses and Doctors both in the Community and the Hospital.
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
All of the benefits that the game could deliver for the NHS would benefit the WM population. In addition the game has been developed by a WM NHS Trust and as such the publicity and any shared revenue will be focussed on the WM.
Current and planned activity: 
The original game was developed by Coventry and Warwickshire Partnership NHS Trust and Focus Games Ltd has refined and reworked the game to make it more engaging and more likley to suceed as a commercial product. This process was supported byMidTECH Innovations (NHS Innovations West Midlands).

The board game has been tested within the NHS and also by members of patient support groups. Feedback has been positive and we now wish to extend the scope of testing to cover a more sophisticated online version of the game and also to manufacture the board game.
What is the intellectual property status of your innovation?:
The IP is owned by Coventry and Warwickshire Partnership NHS Trust, and used by Focus Games Ltd under licence from them.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Regional Scalability:
This game is designed to be used anywhere in the UK, and possibly overseas. We have not yet secured the funding to launch the game commercially. However, we have launched many other games that are being used extensively in the UK and overseas so we are confident that the model works.
Measures:
The most practical measure will be the collection of qualitative feedback from users both patients, carers and healthcare professionals. This would include ongoing questions about any changes to lifestyle and treatement adeherence. This being done for many other existing games that we have published. We would also approach independent stakeholders and hope to encourage them to study the efficacy of the game.
Read more
Hide details
Andy Yeoman 24/08/2016 - 15:08 Sign Posted Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Disruptive technology prevents Left Ventricular remodelling post MI & promotes tissue regeneration. Product result of £10M EU investment & 5 years R&D. Biocompatible & Biodegradable product demonstrated pre-clinically in wide range of animal model.
Overview of Innovation:
Cardiac patch is a scaffold structure compatible with in-vitro cell seeding & cell culture used as a vector for cellular therapy in addition to structural support. Numerous applications include curettage & cardiac transmural use in addition to soft tissue engineering such as hernias & vein repair. Scaffold composition comprises poly(caprolactone), alginate & composites thereof with natural polymers such as chitosan & alginate fibroin decorated with a synthetic peptidic hydrogel. Porosity can be tailored with pore range of 10-250µm, permitting angiogenesis and cell seeding. Although the biomaterial can be used independently as a medical device for prosthetic applications, its main tissue engineering function is to enhance cell attachment, growth & differentiation. An extension of the device is its functionalisation with cell signalling agent capacity providing the scaffold with extracellular matrix like micro-environment. Polymeric self-assembled structure is composed of but not limited to peptidic or polyurethane amphiphiles & can be loaded with chemical & biological cues covalently or via entrapment.

To initiate regeneration, the biomaterial must encourage in-vivo revascularisation & promote integration with host tissue. Concurrently, it should biodegrade at the same rate that newly formed tissue replaces it, being removed from the body by natural metabolic pathways without toxic by-products.

The patch provides both a temporary mechanical support to the infarcted myocardium preventing further damage to the surrounding tissue and prevents aneurism formation in the infarcted area whilst regeneration take place

Myocardial infarct treatment
Device can be used for in-vitro & in-vivo applications. Both parts of the device can be loaded with cell signalling agents or drugs for research & clinical use. Fibre based secondary drug delivery structure allows multiple growth factor/drug release with different release profiles as a direct tool for gel functionalisation with patient blood components in-vivo.

The system’s mechanical properties match the tissue it replaces. 3D hydrophobic/hydrophilic scaffold provides mechanical support to a gel that acts as scaffold plasticizer & provides an hydrophilic interface with host environment. The gel can also collect cell signalling agents from its immediate environment. The electrospun fibre based drug delivery system can additionally be used as a complementary tool to the gel for loading with cell signalling agents, drugs etc
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
The leading global trend in interventional cardiology is to adopt less invasive technologies, reducing patient recovery time & improving quality of life.
 
PeptiGelDesign Cardiac Patch treats myocardial infarction (MI). Current treatments are based on medication &/or organ transplantation. Approx. 4,600 heart transplants are carried out pa in Europe & the USA (1,900 EU). Even with current medical management, over 1/3 of acute heart attacks are fatal. Rehabilitation levels following MI are variable with major damage unable to be fully healed. Current treatments to prevent tissue damage post MI include thrombolytic agents. These drugs have greatly reduced morbidity & mortality, but must be administered within a short interval following MI to be effective. Cardiac catheterization & Angioplasty have proven effective in restoring blood flow, but cannot reverse tissue damage. Transplantation is complicated surgery, severely limited by lack of donor organs.


Advantages of cardiac patch over current treatment regimes:
 
• Complements established therapies restoring damaged cardiac muscle ensuring improved contractility function & eliminating CHD related early mortality. Following non-lethal MI current treatments effectively restore blood flow, but cannot reverse tissue damage leading to limited rehabilitation & QoL
 
• Restoration of cardiac function drastically reduces re-infarction rates & need for subsequent interventions.


• Demonstrably increases life expectancy post MI. In cases of CABG (bypass), 5-year mortality rate for target population (patients with abnormal Left Ventricular (LV) function typically caused by MI) is 16.5% vs a mortality rate for patients with normal LV function of 8.5% (50% improvement). We could expect the cardiac patch to reduce mortality of patients undergoing MI to the level of those with normal LV function due to recovery of infarcted heart. Similarly, 5-year mortality rate of 80% for post MI patients undergoing an interventional procedure decreases to 40% - the mortality rate for patients undergoing the same procedure but with normal LV function.


• By enabling recovery of the heart muscle patients improve their NYHA class, suffer less Angina Pectoris, reduced incidence  of re-infarction, need less medication & hospitalization & improve QoL. NB: 10 years post CABG intervention, overall survival rate is 69% vs overall event free rate of 41%, suggesting that a significant portion of patients are surviving but with a fairly low QoL
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
In addition to the many benefits to the wider NHS outlined above, there are specific regional benefits accruing from the adoption of this medical device and treatment regime.
 
The high incidence of Chronic Heart Disease and the costly rehabilitation of patients post heart attack is a recognised priority within the West Midlands population.
 
The cardiac patch offers a minimally invasive and rapidly deployable intervention that will significantly improve the quality of life for patients surviving Myocardial Infarction.
 
In addition, the cost and time savings to the NHS and social care through improving patient outcomes, reduced number of transplants and greater quality of life and increased independence for patients post MI will be significant.
Current and planned activity: 
(See attached document for more information)
PeptiGelDesign is currently engaged with the Liverpool Heart and Chest Hospital.

Wish to partner with NHS and NHS Research Organisations on clinical trials for cardiac patch development.

As our primary target market is the UK, we wish to raise profile within the NHS and work with its stakeholders to bring our technology to the market and ultimately to the patient.
  • Explore if entitled to an  Investigational Device Exemption (IDE) ?
  • Identify sources of funding to support PeptiGelDesign pursuing the further validation.
  • Procurement/Adoption: -  Require routes to GP sales - marketing products to CCGs
  • Evaluation/Validation/Clinical Trial - Need to gain additional validation - seeking a trial centre.
  • Concept Development - This is planned development work but seeking NHS partnership/advice.
Project Assistance required - The Company is interested in locating clinical/academic collaborators for new product development.
What is the intellectual property status of your innovation?:
PeptiGelDesign Ltd is licencing the WO2014044321 and finance patent granting process. Today, the patent has been accepted in USA, EU and Japan and will enter EU countries national phase in December 2016.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Guillaume Saint-Pierre 04/08/2016 - 08:33 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Half a million adults and children in the UK experience severe asthma symptoms despite high dose medication. Air4 offers a non pharmacological treatment of allergic disease using Temperature Laminar Airflow to reduce exposure to allergens in the bed.
Overview of Innovation:
Air4 is a unique, innovative medical device which uses Temperture Laminar Airflow (TLA) technology to protect patients with severe allergic asthma and eczema, from exposure to allergens and other airborne particles (pollens, housedust mite and animal danders etc.) that are in and around the bed at night whilst they sleep. The device has no side effects and can therefore be used for adults and children.

Air4 is installed in the bedroom alongside the bed; air is drawn in the device from the room where it is filtered and cooled to 0.5-0.8 degrees centigrade lower than the ambient temperature. As cool air is heavier than room temperature, gravity ensures the air gradually descends without an excessive breeze or draught creating the patients breathing zone; due to the density of the air in the breathing zone airborne allergens are unable to penetrate and therefore the patient sleeps in an allergen free zone.

In reducing the airborne allergens the device has shown in clinical trials that is has reduced exacerbations and the number of hosptial admissions; it has reduced day and night time symptoms in patients and improved quality of life (health related) and has shown to reduce the number of days off work/school.

Air4 has a Medical Technology Innovation briefing from NICE stating the device is clinically and cost effective.There is also an Innovation Medical Technology Overview  from Helath Improve Scotland showing the device is clinically and cost effective compared to standard treatment.

Using the Air4 in adults or children who are still symptomatic despite maximum inhaler treatment; can avoid long term side effects from oral corticosteroids as well as the regular hospital visits from other treatmenst

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Innovation and adoption / Person centred care
Benefit to NHS:
  • Reduction in exacerbations leading to fewer hospital admissions and clinic visits
  • Reduction in use of rescue medication leading to a reduction in drug spend
  • Reduction in the number of days taken off school and work
  • Cost effective and in some circumstances cost saving treatment. Annual rental cost is offset by the economc savings in medical costs resulting in a net cost to the NHS 
  • Fulfils Care closer to home: encouraging people to live independently; provide greater choice and control over health; Reduce NHS costs and the demands for hospital resources
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
Home based overnight treatment which negates the need for hospital stays.
Improvement in quality of life (HRQLS)
Improvement in sleep
Reduction in the need for rescue medication
Reduction in exacerbations and therefore hospital stays and clinic visits.
Current and planned activity: 
Current Activity: Ongoing UK trial (LASER) with results due in spring 2017 (West Midlands have 2 investigator sites)
                          Working with Innovation Nexus Greater Manchester to support clinicians use of Air4
 Current Device Use: Royal Wolverhampton, Hereford
Planned Device Use: Birmingham Childrens, Sandwell, Worcester
What is the intellectual property status of your innovation?:
IP is held by the company
Current Certification: Class 1 Medical Device; CE Marked
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
Air4 is already being used in several accounts across the West Midlands with several more interested in trying the device. From a company perspective the warehouse will be informed of potential numbers and they will increase production to ensure they can meet with the increase in demand
Measures:
Overall measure of success of our innovation will be to see it accepted as a standard of care treatement for allergic disease and no longer applied for by an IFR for clinical exceptionality.
Quality Measures: Airsonett has implemented a quality management system compliant with ISO 9001, 13485 and QSR
Safety: Air4 is a CE marked class 1 medical device. As it is a non pharmacological device there are no known side effects and the device is installed,set up and removed by trained technicians.
Cost: There has been an economic analysis published in the BMJ Open Respiratory Research which found that the Air4 was a cost effective addition to standard treatment in patients with severe uncontrolled atopic asthma. These high risk patients with severe atopic asthma who use Air4 could reduce the incidence of hospitalization which could be cost saving to the NHS. Brazier et al (2015)         Airsonett® would be added to existing treatment and the average cost of long term treatment is £5.72 per day. Estimated cost of add on therapy currently used in the NHS is Omalizumab at approximately £23 per day.
The cost utility analysis estimated an incremental cost effectiveness ratio (ICER) of £8998 per quality of life adjusted year (QALY) with Airsonett®® compared to NHS standard care based on an incremental cost of £553 and a QALY gain of 0.0615. http://www.nice.org.uk/advice/MIB8/chapter/Technology-overview
People Measures:Success of the device will be measured using the following key performance indicators at 3 months for children and 6 months for adults: Improvement in the Asthma Control Test (ACT); reduction in exacerbations (compared to previous 12 months); reduction in or stopping of oral corticosteroids; Improvement in the Asthma Quality of Life Scores, adult and children (AQLQ: PAQLQ) and also improvement in sleep, work/school, and comorbid allergic disease such as eczema and/or perinnial rhinitis.
Adoption target:
Currently in WM there are 2 sites in the Laser trial (adult) and 2 sites (Paediatrics) who have patients on the device; approximately 5 additional sites across the WM with an interest. Based on the current interested sites I would estimate in the first year approximately 30 patients.
Read more
Hide details
Sarah Renshaw 03/08/2016 - 13:59 Detailed Submission 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
LiverMultiScan is an FDA 510(k) cleared and CE marked MRI technology that provides a quantitative assessment of liver health, including fibroinflammatory disease, steatosis and iron, all in a non-contrast 5 minute scan.
Overview of Innovation:
Perspectum Diagnostics is a medical imaging company with an ISO 13485 compliant CoreLab. The company has developed novel imaging technology, LiverMultiScan, an MRI-based non-invasive tool that has attained CE-marking and FDA 510(k) clearance to aid the diagnosis of patients with chronic liver disease.
LiverMultiScan (and LiverMultiScan Discover for clinical trial use) can characterise liver tissue in three ways, providing accurate measurements of liver fat, hepatic iron content and fibro-inflammatory disease, using the proprietary Liver Inflammation and Fibrosis (LIF) score. The LIF score has been shown to stratify NAFLD and NASH patients (Pavlides, 2015), correlate with histological markers of inflammation and fibrosis (Banerjee, 2014), and most importantly, is the first imaging test to predict liver-related clinical outcomes (Pavlides, 2016). It is the only liver imaging technology included in the UK Biobank study, with 100,000 scans to be performed in the coming years (Kelly, 2015).
Available as a Quantitative Analysis Service (QAS), LiverMultiScan has been cleared as an imaging tool to aid the diagnosis of early liver disease. It offers a standardised and high-quality method for supporting Gastroenterology/Hepatology and Radiology departments in diagnosis and monitoring of the liver in clinical settings and studies, and has potential to streamline clinical management by compressing the diagnostic pathway. Perspectum is also supporting multiple international clinical trials with LiverMultiScan Discover.
  • Banerjee et al. (2014) Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 60:69-77.
  • Kelly et al. (2015) Predicted prevalence of NAFLD and NASH in a large population using non-invasive multiparametric MRI. AASLD 2015. Abstract ID: 931.
  • Pavlides et al. (2015) Multi-parametric magnetic resonance can accurately assess NAFLD histological disease severity; comparison with transient elastography. AASLD 2015. Abstract ID: 2190.
  • Pavlides et al. (2016) Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 64:308-315.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wealth creation / Clinical trials and evidence / Digital health / Patient and medicines safety
Benefit to NHS:
The utility of LiverMultiScan for assessing fibroinflammatory disease, steatosis and predicting clinical outcomes means it is well-positioned to reduce (and potentially remove) the need to perform invasive liver biopsies. It also facilitates longitudinal monitoring, which is near impossible with current sampling technology.
According to a recent NIHR HTA report, the cost of a liver biopsy is £956, but this can increase significantly with complications (clinically significant bleeding in 1.1 – 1.6%). For healthcare providers, liver biopsies are unappealing because of the attendant risk, financial cost, lack of reliability (as sampling only 0.002% of the liver volume), and uncertainty in interpretation. Nevertheless, primarily because there has not been a viable alternative, it is estimated that 650,000 liver biopsies are performed annually worldwide. 
There are substantial costs associated with managing patients with NAFLD, in particular for those patients progressing to NASH who are at significant risk of cirrhosis, HCC and liver failure. Although pharmacologic options are limited, there are numerous clinical trials ongoing.
Available treatment options increase (e.g., diet, surgery), outcomes improve and healthcare costs decrease the earlier those with, or at risk of, more advanced disease are identified. When combined with the rising incidence of NAFLD and NASH, the availability of a non-invasive test for accurately assessing fibroinflammatory disease, steatosis and predicting clinical outcomes, is vital.
A recent health economic study (submitted for publication) from the University of Birmingham concluded that LiverMultiScan is cost effective either as an adjunct to or replacement of Fibroscan in the diagnostic pathway of NAFLD. In addition, the utility of LiverMultiScan in reducing the proportion of patients with suspected NAFLD undergoing hospital consultations and/or liver biopsies is currently being evaluated in a large Europe-wide multicentre clinical trial (including the UK).
LiverMultiScan could allow:
  • A faster throughput and diagnostic analysis than conventional sampling – reducing patient lists and identifying those that need and do not need clinical intervention.
  • Regular monitoring of patients without painful invasive and potentially dangerous biopsies.
  • A less traumatic assessment of liver disease in children.
  • Assessment of liver health in other diseases (e.g., viral hepatitis, alcoholic liver disease)
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Liver disease is the fifth ‘big killer’ in England and Wales, after heart, cancer, stroke and respiratory disease (http://www.britishlivertrust.org.uk/about-us/media-centre/facts-about-liver-disease), with twice as many people dying from liver disease now compared to 1991.
In a European study, the healthcare costs for patients with NAFLD were 26% higher than for those without the disease (Baumeister, 2008). In the US, the direct costs of cirrhosis and chronic liver disease were estimated to by $2.5 billion, whereas indirect costs were estimated to be $10.6 billion (Ruhl, 2008).
Identifying those with, or at risk of, more advanced liver disease earlier increases treatment options available, reduces healthcare costs and improves outcomes. Benefitting both the NHS and wider West Midlands community.
This diagnostic test could also be used to aid the diagnosis and monitoring of liver disease in children, with a European clinical trial underway.
 
  • Baumeister et al. (2008) Impact of fatty liver disease on health care utilization and costs in a general population: A 5-year observation. Gastroenterology. 134:85.
  • Ruhl et al. (2008) Costs of digestive disease. In The Burden of Digestive Disease in the United States. NIH Publication. pp 137-143.
Current and planned activity: 
LiverMultiScan currently in use at University Hospitals in Birmingham, Edinburgh, Oxford Southampton & Kings College London (KCL). Discussions with other NHS sites

Recent completion of large Innovate UK funded 2.5 year study at University Hospitals Birmingham & Edinburgh to develop & validate against liver biopsy

KCL is UK site for large EU multi-centre clinical trial to evaluate cost-effectiveness of LiverMultiScan in primary care pathway.

Patient study - 100 patients with history of liver disease receive LiverMultiScan, nearing completion with extremely +ve feedback

LiverMultiScan is only liver imaging technology in UK Biobank - 100,000 subjects to be imaged

Planned activity
West Midlands location of choice as:
  • Build on relationship with University of Birmingham following 2.5 yr study
  • West Midland’s considerable expertise in liver disease
  • Large patient cohort and trials infrastructure
  • Involve Children’s Hospital in study
  • Dr Banerjee, founder & CEO, visiting Hon. Consultant Hepatologist at UHB
What is the intellectual property status of your innovation?:
Perspectum holds or exclusively licenses 7 patent applications in the UK and other territories. To date, one has been granted in the UK (GB2497668).
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Matt Kelly 03/08/2016 - 10:07 Publish Login or Register to post comments
0
0
Votes
-99999

Active Campaigns